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Abstract
Within the framework of the Health Protection Agency’s pro-
gramme of enhanced surveillance of Staphylococcus aureus with
Panton–Valentine Leucocidin (PVL-SA) in England and Wales
conducted during 2005–2006, we identiﬁed 720 PVL-SA, repre-
senting a two-fold increase between 2005 (n = 224) and 2006
(n = 496). The number of PVL-methicillin-resistant S. aureus rose
from 119 to 159 in that period. Isolates were referred by 112
centres and included outbreaks of PVL-related disease in com-
munity and healthcare settings. One hundred individuals had sys-
temic disease symptoms. Planned systematic surveillance-based
studies aim to better address the question of whether these
increases reﬂect an increasing prevalence of PVL-SA and/or
improved case ascertainment of PVL-related syndromes.
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Community-associated (CA) methicillin-resistant Staphylococ-
cus aureus (MRSA) strains are causing great concern in
healthcare and community settings [1,2]. CA-MRSA may
encode Panton–Valentine Leucocidin (PVL) and can be highly
virulent [1]. PVL-related disease is most often manifested as
skin and soft tissue infection (ranging from superﬁcial to
complicated deep-seated infection) [3], although more seri-
ous diseases, such as necrotizing fasciitis [4], purpura fulmin-
ans [5] and necrotizing pneumonia, have been identiﬁed with
mortality rates of up to 75% [6]. Individually, neither meticil-
lin resistance nor PVL production are new phenomena in the
UK. PVL-negative MRSA clones (most notably UK EMRSA-15
and -16) have been prevalent for 15 years or more in the
UK healthcare system, and PVL-encoding meticillin-sensitive
S. aureus (MSSA) phage-type 80/81 clones caused consider-
able morbidity in both community and healthcare settings in
the 1950s and 60s [7]. However, the global emergence of
clones that combine meticillin resistance and PVL production
(PVL-MRSA) has occurred only relatively recently [8], albeit
within the context of improved vigilance, case recognition
and microbiological testing initiatives.
The widely-reported association of PVL-MRSA with
sporadic life-threatening disease and outbreaks of skin and
soft tissue infections (SSTIs) among previously healthy indi-
viduals [1,8] herald a new global public health challenge. In
the UK, patient deaths associated with PVL-MSSA and PVL-
MRSA infections have been reported [9,10], and the ﬁrst
known instance (in the UK) of nosocomial transmission of a
PVL-MRSA strain associated with fatalities occurred in 2005–
2006 [9]. In the present study, we discuss the emerging
picture of the epidemiology of both methicillin-susceptible
and -resistant S. aureus with PVL (PVL-SA) in England and
Wales, and relate this to trends in the number of PVL-SA
identiﬁed by the Health Protection Agency’s (HPA) Staphylo-
coccus Reference Unit (SRU) during 2005–2006.
SRU receives S. aureus isolates from many centres in all
regions across England and Wales for characterization and
outbreak investigation purposes. In an attempt to enhance
surveillance and increase case ascertainment of PVL-related
disease, the HPA issued alerts and encouraged referral of
S. aureus isolates from patients with necrotizing SSTIs or
necrotizing pneumonia, as well as ciproﬂoxacin-sensitive
MRSA as a marker of putative CA-MRSA. Of 3380 S. aureus
isolates tested for PVL during 2005 and 2006, we detected a
total of 720 PVL-SA, representing a two-fold year-on-year
increase in the numbers identiﬁed (Table 1). From these
data, it is not possible to ascertain to what degree this rise
is attributable to heightened awareness and concomitant
improved levels of case ascertainment, and/or a genuine
increase in prevalence of PVL-SA isolates in England and
Wales. Similarly, although a total of 112 geographically-dis-
persed centres throughout all geographic regions referred
PVL-SA isolates, differences in referral patterns and clinical
practice between centres (e.g. empirical management without
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samples being submitted for microbiological testing), as well
a bias towards more serious infections, preclude reliable
conclusions regarding the overall patterns of disease at a
regional and/or national level.
In the USA, CA-MRSA have expanded the traditional risk
categories for MRSA infection (i.e. beyond the very young, the
old, and the sick along with recent healthcare contact) [11].
Although the PVL-positive, MRSA strain USA300 has become
endemic in multiple healthcare establishments in the USA
[12,13], it is not the predominant PVL-MRSA strain seen in the
UK (17th European Congress of Clinical Microbiology and
Infectious Diseases, Abstract 1732). Nevertheless, our data
support an expansion of risk categories for both PVL-MSSA
and PVL-MRSA infections observed internationally [8,11].
Among the 627/720 individuals for which data were available,
26% and 35% were £16 and 17–40 years old, respectively.
From replies to questionnaires issued for referred isolates,
location data were available for 702 of the 720 cases, and indi-
cated that 502/702 cases (72%) were identiﬁed in individuals in
the community. The majority (398/513; 78%) of PVL-SA were
from individuals who had SSTIs (Table 2); 115/513 (22%) were
from patients with more serious or systemic disease. A total
of 21 fatal cases (16 MSSA; ﬁve MRSA) were identiﬁed, repre-
senting 4% of the 513 for which clinical details were available.
Eight of the fatal cases presented with severe community-
acquired pneumonia (average age 38 years).
PVL-SA were identiﬁed in individuals in previously recog-
nized risk groups: school children, nursing home residents,
military service personnel, household contacts of individuals
with PVL-SA disease, injecting drug users and men who have
sex with men. The majority of the 720 isolates detected in
this study were associated with sporadic infection. However,
a small number of community outbreaks and three health-
care-associated outbreaks were observed, some of which
were reported in the national press and elsewhere [9]. One
outbreak in particular highlighted the ﬁtness and pathogenic
potential of PVL-MRSA strains, with concurrent community
and nosocomial spread affecting 17 individuals, two of whom
died [9]. Although the number of reported instances of
nosocomial spread of PVL-MRSA in the UK remains small,
the spectre of a successful meticillin-resistant, PVL-positive
strain, such as the USA300 clone becoming more prevalent
in UK community and/or healthcare settings, gives cause for
concern.
Overall, our data support an increasing trend in PVL-SA
during 2005–2006 (Table 1). However, these data are likely
TABLE 1. Panton–Valentine Leucocidin (PVL)-positive Staph-
ylococcus aureus identiﬁed during 2005 and 2006: patient
demographics
Patient MSSA PVL+ MRSA PVL+ Total PVL+
Age (years) Sex 2005 2006 2005 2006 2005 2006
0–16 Male 13 31 25 25 38 56
Female 6 35 13 18 19 53
17–40 Male 27 48 19 41 46 89
Female 11 39 16 20 27 59
41–60 Male 5 23 9 11 14 34
Female 4 27 4 11 8 38
>60 Male 3 36 10 7 13 43
Female 11 61 12 6 23 67
NA NA 27 37 9 20 36 57
Total 107 337 117 159 224 496
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, meticillin-sensitive
S. aureus; NA, data not available.
TABLE 2. Association of Staphylococcus aureus with Panton–Valentine Leucocidin with clinical disease
Infection type Infection details
No. of individuals affected
PVL-MSSA (n) PVL-MRSA (n) Total % of infectionsa
Skin and soft tissue infections Boils/abscesses 148 88 236 46
Cellulitis 29 15 44 9
Insect bites – 6 6 1
Wounds 52 33 83 16
Ulcers 5 5 10 2
Otitis media – 6 6 1
Blisters, eczema, impetigo 3 10 13 3
Respiratory tract infection Upper respiratory tract infection 3 9 15 3
Pneumonia/necrotizing pneumonia 36 8 44 9
Necrotizing fasciitis 1 – 1 <1
Purpura fulminans 1 – 1 <1
Bacteraemia 17 12 24 5
Septic shock 14 1 16 3
Other invasive infections including e.g. line infection and septic arthritis 8 4 14 3
Screeningb 53 44 99 NA
Clinical data not available 75 34 108 NA
Total 445 275 720
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, meticillin-sensitive S. aureus; NA, not applicable.
aNumber of Staphylococcus aureus with Panton–Valentine Leucocidin (PVL-SA) recovered from infection = 513.
bIncludes: nose, throat and/or perineum swabs from (i) individuals with a history of suspected PVL-related infection(s), (ii) close contacts of PVL-SA cases.
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to reﬂect an underestimate of PVL-related disease as a result
of the aforementioned factors inﬂuencing case ascertainment.
Moreover, when isolates are referred for testing, the pre-
sumptive identiﬁcation of PVL-MSSA often relies upon
alert healthcare professionals recognizing and suspecting
PVL-related disease in order to trigger further testing. For
PVL-MRSA, presumptive identiﬁcation is more amenable via
the use of routinely tested ‘surrogate’ markers, such as oxa-
cillin resistance and ciproﬂoxacin susceptibility combined
with clinical data suggestive of PVL-related disease. The
apparent building levels of ciproﬂoxacin resistance among
some PVL-MRSA strains has led to some contention over
the use of this marker for presumptive identiﬁcation of
PVL-MRSA, but the majority of PVL-MRSA herein identiﬁed
remain susceptible to ciproﬂoxacin (47th Annual Meeting of
the Interscience Conference on Antimicrobial Agents and
Chemotherapy, Abstract 1083), indicating that it remains of
some utility in the UK, for the time being at least.
It is likely that the clinical burden of PVL-related disease
remains underestimated in the UK, potentially impacting on
clinical and therapeutic management particularly where the
aetiological agent is PVL-MRSA in a community setting.
Improvements in surveillance and case ascertainment are
required to establish the burden of disease, associated risk
factors, and provide an evidence-based guidance for effective
patient management and infection control strategies. To this
end, we would like to continue to encourage the submission
of S. aureus from suspected PVL-related syndromes (e.g.
recurrent boils, necrotizing SSTIs and necrotizing pneumonia)
to the SRU for analysis. Furthermore, we will shortly
augment the HPA’s enhanced surveillance initiative with a
systematic study to determine the prevalence of PVL in the
population at large to gain a better understanding of the
burden of PVL disease in England and Wales.
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